Find a job

Subscribe for free

All things Pharma

NICE opts for cheapest vasodilator

 NICE has recommended naftidrofuryl oxalate for the treatment of people who have intermittent claudication caused by peripheral arterial disease (PAD) in final guidance.

The generic version of Praxilene was recommended in favour of Pletal (Cilostazol), Trental 400 (Pentoxifylline) and Hepoxal (Inositol nicotinate) after it was shown to be more clinically and cost-effective.

Dr Carole Longson, Health Technology Evaluation Centre Director at NICE, says the Institute is pleased to recommend the vasodilator for treating a condition that can have “a significant impact” on individuals.

Intermittent claudication, and the pain associated with it, occurs when muscles are starved of oxygen as a result of PAD narrowing arteries.

The final guidance recommends that alongside the branded Praxilene, naftidrofuryl oxalate is also available as a cheaper, generic preparation and that treatment should be started with the least costly option.

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription